Search

Abstract Introduction The quality of care and patient satisfaction is closely linked with dignity, which is a crucial component of therapy and care. However, there is very little study on dignity in the context of mental health care. Planning for ongoing patient care might benefit from an understanding of the notion of dignity by exploring the experiences of patients, caregivers and companions of patients who have a history of hospitalization in mental health institutions. To retain patients' dignity while they were being treated in mental wards, this study sought to understand the experiences of patients, caregivers and companions of patients. Materials and Methods This investigation was qualitative. Semistructured interviews and focus groups were utilized to collect the data. The purposeful sampling method was employed for participant recruitment, which continued until data saturation. Two focus group discussions and 27 interviews were conducted. Participants included 8 patients, 2 patients' family members (companions), 3 psychologists, 4 nurses and 11 psychiatrists. Two focus group discussions were held with seven family members or companions of patients. Thematic analysis was used for data analysis. Results The primary theme that emerged was the infringement of patients' dignity, through negative guardianship, dehumanization and violations of their rights. Subthemes included dehumanization, worthlessness and namelessness, patient rights violations and stripping patients of authority. Conclusion Our results suggest that, regardless of the severity of the illness, the nature of psychiatric illness significantly compromises patients' dignity. Mental health practitioners, due to their sense of guardianship, may unintentionally treat patients with mental health disorders, thus compromising the patient's dignity. Patient or Public Contribution The research team's experiences as a psychiatrist, doctor and nurse informed the study's objectives. Nurses and psychiatrists who work in the healthcare industry designed and conducted the study. The primary authors, who are healthcare providers, collected and analysed the required data. Furthermore, the entire study team contributed to the writing of the manuscript. Study participants were involved in the data collection and analysis.

Introduction: Leishmaniasis caused by Leishmania spp. is observed in most parts of the world. Although, glucantime, a pentavalent antimony compound, and other synthetic drugs are broadly applied for leishmaniasis therapy; however, the use of these synthetic agents has some limitations. Hence, this study was designed to assess the inhibiting effects of 7-hydroxy4′-methoxyisoflavone (7HMI) against promastigote and amastigote stages of Leishmania major in vitro. Methods: The MTT assay was applied to study the antileishmanial activity of 7HMI against promastigotes and its cytotoxicity effects on macrophage cells. The nitric oxide (NO) produced by the treated macrophage cells with 7HMI was also assessed. Results: 7HMI considerably (P

Introduction: Recent studies have reported that Astragalus spp. can display various biological effects, e.g., anticancer, antioxidant, antimicrobial, neuroprotective, and hepatoprotective activities. Here we decided to assess the ameliorating effects of Astragalus maximus methanolic extract (AMME) on inflammation and oxidative stress in streptozotocin-induced diabetic rats. Methods: The dried aerial parts were extracted by maceration technique with 70% methanol. Diabetes was induced in rats via intraperitoneal injection of streptozotocin at 65 mg/kg. Diabetic rats orally received AMME at 75-30 mg/kg for 28 days. The serum levels of glucose, insulin, liver enzymes, bilirubin, creatinine (Cr), urea (Ur), triglyceride, and cholesterol, as well as the tissue levels of oxidant/antioxidant enzymes and pro-inflammatory cytokines were evaluated by the diagnostic kits. The level of α-amylase inhibition by AMME was also determined. Results: AMME (150 and 300 mg/kg) treatment significantly reduced (P

Most studies have shown the positive effects of lavender inhalation in decreasing anxiety in patients with cardiovascular diseases. We aimed to systematically review the role of aromatherapy with lavender in these patients. By PRISMA standards, we explored the studies on the role of aromatherapy with lavender in reducing the anxiety of patients with cardiovascular diseases in English databases through the words and terms "aromatherapy", "lavender", "lavandula", "anxiety", "cardiovascular diseases". Out of 16 647 papers, 12 papers up to January 2022 encountered the inclusion criteria for involving in this systematic review. The majority of studies (7 studies, 70%) were used Spielberger Standard Questionnaire as a measurement scale for their studies. Lavender aromatherapy was mostly used for myocardial infarction (3 studies, 30%) and coronary artery bypass graft (CABG) surgery (3 studies, 30%) patients. We concluded that aromatherapy with lavender essential oil significantly ameliorated the anxiety signs in some cardiovascular diseases, e.g., CABG surgery, myocardial infarction, and cardiac ischemia; however, more studies are required in this field to obtain more specific evidence.